CENMIRA
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

CENMIRA Trademark

Serial Number: 88749349

CENMIRA is a trademark filed by TEVA Pharmaceutical Industries Limited on January 7, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

TEVA Pharmaceutical Industries Limited (147 trademarks)

Science Based Industries Campus
Tel Aviv 6944020 , IL

Entity Type: 99

Trademark Details

Filing Date

January 7, 2020

Registration Date

Not Registered

Published for Opposition

May 19, 2020

Goods & Services

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Aug 14, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Aug 14, 2023 ABN6
ASSIGNED TO EXAMINER
Jun 29, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 2, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 2, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 2, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 2, 2023 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 26, 2023 EXRA
SOU EXTENSION 5 GRANTED
Jan 25, 2023 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 25, 2023 AITU
SOU EXTENSION 5 FILED
Jan 9, 2023 EXT5
SOU TEAS EXTENSION RECEIVED
Jan 9, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 16, 2022 EXRA
SOU EXTENSION 4 GRANTED
Jul 14, 2022 EX4G
SOU EXTENSION 4 FILED
Jul 14, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 14, 2022 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 7, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 7, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 7, 2022 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 8, 2022 EXRA
SOU EXTENSION 3 GRANTED
Jan 6, 2022 EX3G
SOU EXTENSION 3 FILED
Jan 6, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 6, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 15, 2021 EXRA
SOU EXTENSION 2 GRANTED
Jul 13, 2021 EX2G
SOU EXTENSION 2 FILED
Jul 13, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 13, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 18, 2020 EXRA
SOU EXTENSION 1 GRANTED
Dec 16, 2020 EX1G
SOU EXTENSION 1 FILED
Dec 16, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 16, 2020 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 14, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 19, 2020 NPUB
PUBLISHED FOR OPPOSITION
May 19, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 29, 2020 NONP
ASSIGNED TO LIE
Apr 10, 2020 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 3, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 1, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 1, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 1, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 1, 2020 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 27, 2020 GNRN
NON-FINAL ACTION E-MAILED
Mar 27, 2020 GNRT
NON-FINAL ACTION WRITTEN
Mar 27, 2020 CNRT
ASSIGNED TO EXAMINER
Mar 26, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 10, 2020 NWOS
NEW APPLICATION ENTERED
Jan 10, 2020 NWAP